The Prostate Cancer Therapeutics Market Forecast 2015-2025

LONDON, August 25, 2015 /PRNewswire/ --

Opportunities For Leading Companies 

Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 225-page report provides 192 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this nascent pharmaceutical market.

Forecasts from 2015-2025 and other analyses show you commercial prospects 

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis), product profiles and commercial developments. Read the full transcripts of one exclusive expert opinion interview from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales, including:
• Dr Katarzyna Nej-Wolosiak, Medical Science Lead, SOTIO

See revenue forecasts for the most promising products in development
How will leading prostate cancer drugs and devices perform to 2025 at world level? Our study forecasts sales of 9 leading drugs, including:
• Zytiga
• Xtandi
• Xofigo
• Lupron
• Zoladex
• Taxotere
• Provenge

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Furthermore, this report will show your revenue forecast to 2025 for 5 leading procedures:
• Brachytherapy
• Radical prostatectomy
• External beam radiation
• Cryotherapy
• HIFU

Discover how high revenues can go. Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries? 

In addition to analyses of the overall world market, you discover individual revenue forecasts to 2025 for:
• US
• EU5 (Germany, France, Italy, Spain and the UK)
• Japan
• South Korea
• India
• China
• Brazil
• Russia
• Mexico
• Rest of the World

There will be growth in both developed and developing pharmaceutical markets. Our analyses show that the "Rest of the world" market will achieve high revenue growth by 2025.

Leading companies and potential for market growth 

Overall, world revenue for prostate cancer therapies will reach $8.3bn in 2015, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, an increasing patient population and diagnostic rates will result in a significant increase in sales over the next decade.

See visiongain's analysis of 7 leading companies, including these:
• Johnson & Johnson
• AstraZeneca
• Varian Medical Systems
• Elekta
• Sanofi
• AbbVie
• Theragenics

A company profile gives you the following information where available:
• Historical revenues
• Discussion of a company's activities and outlook, including promising pipeline products
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development - assess innovation, trends and possibilities 

What about R&D - the pipeline for new drugs? You see trends for these areas and technologies:
• Immunotherapies
• Gene therapies
• Androgen Receptor Antagonists

New prostate cancer drugs are in great demand to allow patients more personalised treatment plans. Our work explains, discussing many issues.

How the Prostate Cancer Therapeutics Market Forecast 2015-2025: Opportunities for Leading Companies report helps you
In summary, our 225 page report gives you the following knowledge:
• Market forecasts to 2025 for the prostate cancer drugs and devices markets - find out what the next decade holds for both markets, assessing annual growth rates and market shares.
• Revenue forecasts to 2025 for the leading national markets
• Predicted revenues of 9 leading drugs to 2025 - see potentials of top products
• Assessment of 7 leading companies - hear about products, results and strategies including pipeline analysis and recent developments
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Information found nowhere else 

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the prostate cancer therapeutics market and leading the leading companies. You find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)20-7336-6100

Or click on https://goo.gl/90hs2U

Companies Listed
Accord Healthcare Inc
Actavis Inc
Active Biotech/Ipsen
Advanced Medical Isotope Corporation (ADMB)
Advantagene
Advaxix Inc
Agensys
Algeta
AliosBioPharma
Amgen
Aragon Pharmaceuticals
Astellas
AstraZeneca
Bavarian Nordic
Bayer
Beckman Coulter (Danaher)
Bellicum Pharmaceuticals
Bostwick Laboratories
Bristol Myers Squibb
Computer Motion
Couagen AG
Cougar Biotechnology (Johnson & Johnson)
CP Medical (Theragenics)
CR Bard
Dendreon
Dendreon Corporation
EDAP TMS
Elekta
EMD Serono
Exelixis
Galt Medical (Theragenics)
GenomeDx Biosciences
Genomic Health
Hologic
Hospira
Immunocore limited
Intuitive Surgical
Iris International (Danaher)
Janssen
Johnson&Johnson
Kyowa Hakko Kirin
Macrogenics
MDxHealth
Medivation/Astellas Pharma
Merck & Co. (Merck)
Metabolon
Metamark Genetics
Millenium Pharmaceuticals
Mitomics
Mylan Pharmaceuticals
Myriad Genetics
NorthWest Biotherapeutics
Nucletron
OncoGenex
Oncura
Opko Health
Pharmacyclics
Progenics Pharmaceuticals
Radon Ltd (Elekta)
Regeneron
Roche
Sandoz
Sanofi
Seattle Genetics
Siemens Healthcare
SonaCare Medical
SOTIO
Steba Biotech
Sun Pharmaceuticals
Sython Pharmaceuticals
Takeda Pharmaceutical Company
Teva
Tokai Pharmaceuticals
Varian Medical Systems
Zydus Pharmaceuticals 

Other Organisations Mentioned in this Report
American Cancer Society (ACS)
American Society of Clinical Oncology (ASCO)
American Society of Gene and Cellular Therapy (ASGCT)
Brazilian Industrial Biotech Association
Brigham Young University
Carnegie Institution for Science
Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia)
European Medicines Agency (EMA)
European Patent Office (EPO)
Georgetown University
Hannover Medical School
Kunshan RNAi Institute
Mary Crowley Cancer Research Centre
Max Planck Institute
MD Anderson Cancer Center
Ministry of Science and Technology (India)
National Institute for Health and Care Excellence (NICE) (UK)
National Institutes of Health (NIH) (US)
Ohio State University (OSU)
Pachyonychia Congenita Project
United States Food and Drug Administration (FDA)
University of Bayreuth
University of Calgary
University of Helsinki
University of Massachusetts Medical School
University of Oxford
University of Pittsburgh
US Department of Defense
Wellcome Trust
World Health Organization (WHO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)20-7336-6100

Or click on https://goo.gl/90hs2U

SOURCE Visiongain